News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
130,185 Results
Type
Article (4688)
Company Profile (18)
Press Release (125479)
Section
Business (36473)
Career Advice (109)
Deals (6220)
Drug Delivery (6)
Drug Development (11589)
Employer Resources (11)
FDA (4076)
Job Trends (2937)
News (59236)
Policy (4865)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (1)
2024 BioMidwest Digital (3)
2024 Bio NC Digital (1)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
Academia (402)
Accelerated approval (1)
Allergies (17)
Alliances (12103)
ALS (14)
Alzheimer's disease (379)
Antibody-drug conjugate (ADC) (9)
Approvals (4128)
Artificial intelligence (88)
Autoimmune disease (3)
Automation (4)
Bankruptcy (50)
Best Places to Work (2630)
BIOSECURE Act (1)
Biosimilars (15)
Biotechnology (10)
Bladder cancer (26)
Brain cancer (7)
Breast cancer (106)
Cancer (678)
Cardiovascular disease (44)
Career advice (100)
Career pathing (1)
CAR-T (13)
Cell therapy (45)
Cervical cancer (10)
Clinical research (9913)
Collaboration (217)
Compensation (70)
Complete response letters (1)
COVID-19 (583)
CRISPR (1)
C-suite (40)
Cystic fibrosis (18)
Data (577)
Decentralized trials (1)
Depression (11)
Diabetes (51)
Diagnostics (5822)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (3)
Drug discovery (21)
Drug pricing (3)
Drug shortages (2)
Duchenne muscular dystrophy (9)
Earnings (13522)
Employer branding (2)
Employer resources (11)
Events (17093)
Executive appointments (135)
FDA (4408)
Featured Employer (2)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (156)
Gene editing (3)
Generative AI (8)
Gene therapy (37)
GLP-1 (67)
Government (726)
Guidances (11)
Healthcare (3444)
IgA nephropathy (2)
Immunology and inflammation (9)
Indications (8)
Infectious disease (629)
Inflammatory bowel disease (20)
Influenza (19)
Intellectual property (13)
Interviews (12)
IPO (2401)
IRA (1)
Job creations (473)
Job search strategy (95)
Kidney cancer (6)
Labor market (1)
Layoffs (29)
Leadership (1)
Legal (601)
Liver cancer (16)
Lung cancer (112)
Lymphoma (50)
Machine learning (1)
Management (3)
Manufacturing (59)
MASH (9)
Medical device (2771)
Medtech (2771)
Mergers & acquisitions (3951)
Metabolic disorders (86)
Multiple sclerosis (23)
NASH (3)
Neurodegenerative disease (16)
Neuropsychiatric disorders (2)
Neuroscience (476)
NextGen: Class of 2025 (798)
Non-profit (632)
Northern California (508)
Now hiring (2)
Obesity (29)
Opinion (12)
Ovarian cancer (20)
Pain (6)
Pancreatic cancer (17)
Parkinson's disease (28)
Partnered (3)
Patents (31)
Patient recruitment (15)
Peanut (8)
People (9647)
Pharmaceutical (2)
Phase I (2422)
Phase II (4265)
Phase III (4015)
Pipeline (237)
Policy (3)
Postmarket research (490)
Preclinical (936)
Press Release (13)
Prostate cancer (46)
Psychedelics (1)
Radiopharmaceuticals (126)
Rare diseases (48)
Real estate (958)
Recruiting (5)
Regulatory (4017)
Reports (12)
Research institute (464)
Resumes & cover letters (15)
Rett syndrome (1)
RSV (7)
Schizophrenia (8)
Series A (17)
Series B (13)
Service/supplier (2)
Sickle cell disease (5)
Southern California (386)
Spinal muscular atrophy (18)
Sponsored (6)
Startups (656)
Stomach cancer (3)
Supply chain (8)
Tariffs (1)
The Weekly (2)
United States (4962)
Vaccines (73)
Venture capitalists (6)
Weight loss (5)
Women's health (6)
Date
Today (24)
Last 7 days (105)
Last 30 days (518)
Last 365 days (7394)
2025 (2328)
2024 (7293)
2023 (8065)
2022 (12400)
2021 (12048)
2020 (11017)
2019 (7564)
2018 (5877)
2017 (6521)
2016 (6321)
2015 (7335)
2014 (5366)
2013 (4587)
2012 (4974)
2011 (5169)
2010 (4605)
Location
Africa (132)
Alabama (7)
Alaska (1)
Arizona (58)
Arkansas (2)
Asia (6451)
Australia (1401)
California (1096)
Canada (346)
China (62)
Colorado (72)
Connecticut (102)
Delaware (49)
Europe (18286)
Florida (123)
Georgia (43)
Idaho (4)
Illinois (136)
India (8)
Indiana (55)
Iowa (4)
Japan (51)
Kansas (11)
Kentucky (5)
Louisiana (1)
Maine (20)
Maryland (131)
Massachusetts (732)
Michigan (71)
Minnesota (80)
Missouri (29)
Montana (4)
Nebraska (8)
Nevada (2)
New Hampshire (21)
New Jersey (484)
New Mexico (17)
New York (451)
North Carolina (542)
North Dakota (7)
Northern California (508)
Ohio (43)
Oklahoma (2)
Oregon (8)
Pennsylvania (144)
Rhode Island (6)
South America (168)
South Carolina (4)
Southern California (386)
Tennessee (33)
Texas (202)
Utah (89)
Virginia (46)
Washington D.C. (8)
Washington State (103)
Wisconsin (34)
130,185 Results for "c2n diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Samsung Invests in C2N Diagnostics
March 13, 2025
·
4 min read
Press Releases
C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom
February 25, 2025
·
4 min read
BioMidwest
C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories
C2N Diagnostics, LLC, which provides exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health, has entered into a non-exclusive agreement with Mayo Clinic Laboratories, for inclusion of C2N’s Precivity tests in Mayo Clinic Laboratories’ test offerings to its clients.
June 27, 2024
·
4 min read
Press Releases
C2N Diagnostics Partners with The Michael J. Fox Foundation to Uncover New Links Between Parkinson’s Disease, Lewy Body Dementia and Alzheimer’s Disease
January 15, 2025
·
5 min read
Drug Development
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer’s Disease to Better Serve Patients
Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N’s efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer’s disease in the U.S.
March 5, 2024
·
3 min read
Press Releases
First Canadian Clinic to Offer C2N’s PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer’s Disease, Joining Global Community in Embracing Breakthrough Technology
January 29, 2025
·
5 min read
BioMidwest
On World Alzheimer’s Day, C2N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach
C2N Diagnostics is marking World Alzheimer’s Day by highlighting the growing international availability of the PrecivityAD2 blood test, a clinical care assay that helps healthcare providers identify amyloid plaques in the brain, which are recognized as key indicators of Alzheimer’s disease.
September 21, 2023
·
5 min read
BioMidwest
C2N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF
C2N Diagnostics, a leader in advanced brain health diagnostics, today announced the release of the PrecivityAD2 blood test, a clinical care assay that meets the standard of care with currently available PET scans and cerebrospinal fluid tests.
August 17, 2023
·
6 min read
BioMidwest
C2N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology
C 2 N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology.
October 25, 2023
·
4 min read
News
C2N Receives Funding from Diagnostics Accelerator to Develop a Decentralized Clinical Mass Spectrometry Solution to Enable High-Performance Alzheimer’s Disease Testing Worldwide
September 25, 2024
·
8 min read
1 of 13,019
Next
